participated in a live symposium in Beijing on October 30, 2010. Initially, Dr. Swarm educated the group on the fundamentals of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the data that supports some of the key decisions behind
Search Results
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski
management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. PLEASE NOTE The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of evidence and consensus of the authors
Robert J. Morgan Jr.
Since the inception of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) around 15 years ago, the Ovarian Cancer Panel has seen major changes in treatment recommendations based on ever increasing knowledge of results and
John H. Ward
NCCN has developed NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of cancer, management of complications, and screening. The NCCN Guidelines, regularly updated, are a fusion of scientific data and expert opinion
, the National Comprehensive Cancer Network (NCCN) launched its new series of NCCN Guidelines for Patients, consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outlining appropriate cancer treatment
increasing pressure to provide high-quality, cost-effective care consistent with evidence-based standards of medical practice. To address this demand, Proventys CDS Oncology was designed to automate the NCCN Clinical Practice Guidelines in Oncology (NCCN
Al B. Benson III
I recently had the pleasure of participating in an important announcement—the launch of NCCN Guidelines for Patients that are directly based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for health care professionals. As
Abdul-Rahman Jazieh, Hamdy A. Azim, Joan McClure, and Mohammad Jahanzeb
Guidelines in Oncology (NCCN Guidelines) became a global phenomenon, with various groups and regions around the world expressing interest in adapting these guidelines. In response, NCCN launched outreach programs to share their extensive experience and
practice guidelines in oncology. Garnering 118 respondents, the guidelines usage survey revealed the physician community's substantial reliance on and regard for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The NCCN Guidelines are
Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem
T he 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ) addresses 4 main tumor groups
